![Minakem Generic APIs](https://www.pharmacompass.com/image/flap/minakem-header-desktop-w27gif-57924.gif)
![Minakem Generic APIs](https://www.pharmacompass.com/image/flap/minakem-header-mobile-w27gif-62411.gif)
API Suppliers
0
US DMFs Filed
0
CEP/COS Certifications
0
JDMFs Filed
0
EU WC
0
Listed Suppliers
0
0
0
USA (Orange Book)
Europe
0
Canada
0
Australia
0
South Africa
0
Uploaded Dossiers
0
U.S. Medicaid
0
Annual Reports
0
0
USFDA Orange Book Patents
0
USFDA Exclusivities
0
Blog #PharmaFlow
0
News
EDQM
0
USP
0
JP
0
Other Listed Suppliers
0
0
https://www.globenewswire.com/news-release/2022/03/22/2407470/0/en/Windtree-Announces-Results-from-Its-Phase-2-Study-of-Lucinactant-for-COVID-19-Associated-Acute-Respiratory-Distress-Syndrome-ARDS-and-Lung-Injury.html
https://www.globenewswire.com/news-release/2022/02/01/2376571/0/en/Windtree-Completes-Enrollment-in-Its-Phase-2-Study-of-Lucinactant-KL4-Surfactant-for-COVID-19-Associated-Lung-Injury-and-Acute-Respiratory-Distress-Syndrome.html
http://windtreetx.investorroom.com/2020-09-29-Windtree-Announces-FDA-Acceptance-of-IND-Application-for-a-Phase-2-Clinical-Trial-Studying-KL4-Surfactant-in-Acute-Lung-Injury-in-Adults-with-COVID-19